SLC25A5: A Potential Drug Target and Biomarker for Fibroblast-Induced Diseases

Target Name: SLC25A5

NCBI ID: G292

SLC25A5

SLC25A5: A Potential Drug Target and Biomarker for Fibroblast-Induced Diseases

Fibroblast-derived growth factors (FGFs) are a family of cytokines that play a crucial role in tissue repair and regeneration. Fibroblasts are a type of cell that produce a wide range of extracellular matrix (ECM) components, including collagen, elastin, and hyaluronic acid. These ECM components are essential for the maintenance of tissue structure and function. Fibroblasts also produce growth factors that promote cell proliferation, migration, and invasion. One of the well-known fibroblasts-derived growth factors is adenine nucleotide translocator 2 (SLC25A5). SLC25A5 is a protein that belongs to the SLC family of transport proteins. It is expressed in a variety of tissues, including fibroblasts, neurons, and endothelial cells. The function of SLC25A5 is to translocate adenine nucleotides (Adenosine) from the cytoplasm to the cell nucleus to regulate the expression of genes involved in cell growth, differentiation, and apoptosis.

SLC25A5 as a Drug Target

SLC25A5 has been identified as a potential drug target for several reasons. First, SLC25A5 is a protein that is expressed in high levels in fibroblasts, which are a type of cell that are known to be resistant to many drugs. This makes SLC25A5 a promising target for drugs that can inhibit its function and lead to the death of fibroblasts. Second, SLC25A5 is involved in the regulation of several cellular processes that are important for human health, such as cell growth, apoptosis, and regeneration. This makes it an attractive target for drugs that can modulate these processes and lead to therapeutic benefits. Finally, SLC25A5 is a protein that is expressed in the nucleus, which means that it is involved in the regulation of gene expression. This makes it an attractive target for drugs that can modulate gene expression and lead to therapeutic benefits.

SLC25A5 as a Biomarker

SLC25A5 can also be used as a biomarker for several reasons. First, SLC25A5 is a protein that is expressed in high levels in fibroblasts, which are a type of cell that are known to be resistant to many drugs. This makes SLC25A5 a promising target for drugs that can inhibit its function and lead to the death of fibroblasts. Second, SLC25A5 is involved in the regulation of several cellular processes that are important for human health, such as cell growth, apoptosis, and regeneration. This makes it an attractive target for drugs that can modulate these processes and lead to therapeutic benefits. Finally, SLC25A5 is a protein that is expressed in the nucleus, which means that it is involved in the regulation of gene expression. This makes it an attractive target for drugs that can modulate gene expression and lead to therapeutic benefits.

Conclusion

In conclusion, SLC25A5 is a protein that has been identified as a potential drug target and biomarker for several reasons. Its high expression levels in fibroblasts and its involvement in the regulation of cellular processes that are important for human health make it an attractive target for drugs that can inhibit its function and lead to therapeutic benefits. Further research is needed to fully understand the function of SLC25A5 and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 25 Member 5

Functions: ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell (By similarity). Cycles between the cytoplasmic-open state (c-state) and the matrix-open state (m-state): operates by the alternating access mechanism with a single substrate-binding site intermittently exposed to either the cytosolic (c-state) or matrix (m-state) side of the inner mitochondrial membrane (By similarity). In addition to its ADP:ATP antiporter activity, also involved in mitochondrial uncoupling and mitochondrial permeability transition pore (mPTP) activity (By similarity). Plays a role in mitochondrial uncoupling by acting as a proton transporter: proton transport uncouples the proton flows via the electron transport chain and ATP synthase to reduce the efficiency of ATP production and cause mitochondrial thermogenesis (By similarity). Proton transporter activity is inhibited by ADP:ATP antiporter activity, suggesting that SLC25A5/ANT2 acts as a master regulator of mitochondrial energy output by maintaining a delicate balance between ATP production (ADP:ATP antiporter activity) and thermogenesis (proton transporter activity) (By similarity). Proton transporter activity requires free fatty acids as cofactor, but does not transport it (By similarity). Probably mediates mitochondrial uncoupling in tissues that do not express UCP1 (By similarity). Also plays a key role in mPTP opening, a non-specific pore that enables free passage of the mitochondrial membranes to solutes of up to 1.5 kDa, and which contributes to cell death (PubMed:31883789). It is however unclear if SLC25A5/ANT2 constitutes a pore-forming component of mPTP or regulates it (By similarity). Acts as a regulator of mitophagy independently of ADP:ATP antiporter activity: promotes mitophagy via interaction with TIMM44, leading to inhibit the presequence translocase TIMM23, thereby promoting stabilization of PINK1 (By similarity). As part of the mitotic spindle-associated MMXD complex it may play a role in chromosome segregation (PubMed:20797633)

The "SLC25A5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets